Published in Hepatology on December 01, 2002
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut (2006) 1.95
Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 1.56
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43
Treatment strategies according to genotype for chronic hepatitis B in children. Ann Transl Med (2016) 1.40
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut (2005) 1.28
Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev (2007) 1.20
Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci (2005) 1.18
Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol (2006) 1.16
Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int (2007) 1.13
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol (2014) 1.10
Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci (2005) 1.05
Distribution of hepatitis B virus genotypes: phylogenetic analysis and virological characteristics of genotype C circulating among HBV carriers in Kolkata, Eastern India. World J Gastroenterol (2006) 1.03
Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol (2005) 1.00
Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon (2011) 0.95
Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol (2014) 0.93
Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H. World J Gastroenterol (2006) 0.93
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol (2003) 0.91
Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. World J Gastroenterol (2005) 0.90
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients. World J Gastroenterol (2005) 0.89
Novel method for genotyping hepatitis B virus on the basis of TaqMan real-time PCR. J Clin Microbiol (2010) 0.88
Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol (2009) 0.88
Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol (2013) 0.87
Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med (2015) 0.86
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Simultaneous genotyping and quantification of hepatitis B virus for genotypes B and C by real-time PCR assay. J Clin Microbiol (2010) 0.84
Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study. Sci Rep (2015) 0.83
Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E. J Virol (2005) 0.82
Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. J Gastroenterol (2008) 0.82
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med (2011) 0.82
Oligonucleotide chip, real-time PCR and sequencing for genotyping of hepatitis B virus. World J Gastroenterol (2007) 0.81
Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol (2014) 0.80
Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol (2014) 0.80
Prevalence of hepatitis B virus genotype D in precore mutants among chronic liver disease patients from New Delhi, India. Dig Dis Sci (2007) 0.79
Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. Virol J (2007) 0.79
What physicians should know about the management of chronic hepatitis B in children: East side story. World J Gastroenterol (2014) 0.79
End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol (2004) 0.79
Baseline predictors of virological response for chronic hepatitis B patients. World J Gastroenterol (2009) 0.78
Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J Gastroenterol (2005) 0.78
Stronger enhancer II/core promoter activities of hepatitis B virus isolates of B2 subgenotype than those of C2 subgenotype. Sci Rep (2016) 0.78
Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran. Iran J Microbiol (2013) 0.78
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China. Sci Rep (2015) 0.77
Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci Rep (2015) 0.77
An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients. Virol J (2011) 0.77
Hepatitis B virus genotyping: is the time ripe for routine clinical use? J Clin Exp Hepatol (2012) 0.77
Anti-HBV activity of TRL mediated by recombinant adenovirus. World J Gastroenterol (2005) 0.77
HBV and HCV therapy. Viruses (2009) 0.76
The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep (2010) 0.76
Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int (2010) 0.76
Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. World J Gastroenterol (2016) 0.76
Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. N Am J Med Sci (2010) 0.75
Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral Transcription via TATA-Binding Protein and Induces Stress Granule Assembly. J Virol (2015) 0.75
Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients. Sci Rep (2016) 0.75
Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2011) 0.75
VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication. World J Gastroenterol (2005) 0.75
Distribution and clinical significance of hepatitis B virus genotypes in Pakistan. BMC Gastroenterol (2016) 0.75
Inhibition of HBV targeted ribonuclease enhanced by introduction of linker. World J Gastroenterol (2003) 0.75
An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. Medicine (Baltimore) (2016) 0.75
Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C. World J Gastroenterol (2008) 0.75
Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. Int J Curr Chem (2011) 0.75
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 2.66
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol (2010) 2.38
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09
Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (2002) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95
Re-weighting the model for end-stage liver disease score components. Gastroenterology (2008) 1.83
Clinical significance of hepatitis B virus genotypes. Hepatology (2002) 1.82
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology (2006) 1.76
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Indications for therapy in hepatitis B. Hepatology (2009) 1.57
When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med (2007) 1.48
Chronic disease management for patients with cirrhosis. Gastroenterology (2010) 1.47
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol (2003) 1.45
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43
Prediction of liver fibrosis in patients with chronic hepatitis B by serum markers. Hepatogastroenterology (2007) 1.43
Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med (2009) 1.42
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Newer markers for hepatocellular carcinoma. Gastroenterology (2004) 1.31
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol (2008) 1.25
Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol (2009) 1.06
Patient decision making about organ quality in liver transplantation. Liver Transpl (2011) 1.04
Management of hepatitis B patients with antiviral resistance. Antivir Ther (2004) 1.02
Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int (2009) 1.01
Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol (2011) 1.00
Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology (2012) 1.00
Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology (2011) 1.00
Viral factors and outcomes of chronic HBV infection. Am J Gastroenterol (2011) 0.98
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol (2010) 0.95
Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics (2002) 0.95
Update on viral hepatitis: 2008. Curr Opin Gastroenterol (2009) 0.93
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol (2004) 0.92
Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol (2004) 0.91
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother (2006) 0.91
Treatment of hepatitis B. J Gastroenterol (2002) 0.90
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology (2012) 0.88
Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol (2004) 0.88
[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. Rom J Gastroenterol (2004) 0.88
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc (2007) 0.87
HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J Hepatol (2013) 0.87
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol (2004) 0.87
Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc (2010) 0.87
Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology (2006) 0.86
Does antiviral therapy prevent recurrence of hepatitis B virus–related hepatocellular carcinoma after curative liver resection? JAMA (2012) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85
Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr (2011) 0.84
Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int (2010) 0.83
Increased incidence of orthopedic fractures in cirrhotic patients: a nationwide population-based study. J Hepatol (2012) 0.83
Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. Clin Vaccine Immunol (2010) 0.81
Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int (2006) 0.81
The dawn of a new era: transforming our domestic response to hepatitis B & C. Gastroenterology (2010) 0.81
Comparative analysis of noninvasive models to predict early liver fibrosis in hepatitis B e Antigen-negative Chronic Hepatitis B. J Clin Gastroenterol (2011) 0.81
Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl (2008) 0.81
Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander? J Gastroenterol Hepatol (2010) 0.81
Update on viral hepatitis: 2005. Curr Opin Gastroenterol (2006) 0.81